Literature DB >> 20683218

Prognostic factors for survival in patients with unresectable pancreatic cancer.

Andreas Weber1, Victoria Kehl, Tobias Mittermeyer, Esther Herberich, Nadine Röthling, Roland M Schmid, Christian Prinz.   

Abstract

OBJECTIVES: In patients with unresectable pancreatic cancer, estimation of individual prognosis is essential to provide the most suitable biliary stent (self-expanding metal stent or plastic stent). The aim of the current study was to determine prognostic factors for survival in patients with unresectable pancreatic cancer after initial biliary drainage. PATIENTS AND METHODS: The current study included 278 patients with unresectable pancreatic cancer. Prognostic factors for survival were analyzed using the Cox proportional hazards model, the Kaplan-Meier survival estimator, and the Wilcoxon test for difference in survival.
RESULTS: In univariate analysis, advanced T stage according to the TNM classification (P = 0.021, Wald test) and the presence of distant metastases (P = 0.001, Wald test) were predictive factors for shorter survival. However, in multivariate analysis, the presence of distant metastasis was the only independent prognostic factor. The median survival time after initial biliary drainage was 3.1 and 6.6 months in patients with and without the presence of distant metastases, respectively.
CONCLUSIONS: The presence of distant metastases was identified as the only independent prognostic factor for survival after initial biliary drainage. A self-expanding metal stent should be systematically chosen for patient without distant metastases, whereas polyethylene plastic stents should be preferred in patients with distant metastases.

Entities:  

Mesh:

Year:  2010        PMID: 20683218     DOI: 10.1097/MPA.0b013e3181e21b1b

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  17 in total

1.  Ferritin as an independent mortality predictor in patients with pancreas cancer. Results of a pilot study.

Authors:  Marta Kalousová; Tomáš Krechler; Marie Jáchymová; Aleš A Kuběna; Aleš Zák; Tomáš Zima
Journal:  Tumour Biol       Date:  2012-08-10

2.  Pathologic Evaluation and Reporting of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Other Tumoral Intraepithelial Neoplasms of Pancreatobiliary Tract: Recommendations of Verona Consensus Meeting.

Authors:  Volkan Adsay; Mari Mino-Kenudson; Toru Furukawa; Olca Basturk; Giuseppe Zamboni; Giovanni Marchegiani; Claudio Bassi; Roberto Salvia; Giuseppe Malleo; Salvatore Paiella; Christopher L Wolfgang; Hanno Matthaei; G Johan Offerhaus; Mustapha Adham; Marco J Bruno; Michelle D Reid; Alyssa Krasinskas; Günter Klöppel; Nobuyuki Ohike; Takuma Tajiri; Kee-Taek Jang; Juan Carlos Roa; Peter Allen; Carlos Fernández-del Castillo; Jin-Young Jang; David S Klimstra; Ralph H Hruban
Journal:  Ann Surg       Date:  2016-01       Impact factor: 12.969

3.  HLA-G impairs host immune response and predicts poor prognosis in pancreatic cancer.

Authors:  Li Zhou; Zhe-Yu Niu; Zhi-Yong Liang; Wei-Xun Zhou; Lei You; Meng-Yi Wang; Lu-Tian Yao; Quan Liao; Yu-Pei Zhao
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

4.  Performance status of patients is the major prognostic factor at all stages of pancreatic cancer.

Authors:  Faruk Tas; Fatma Sen; Hatice Odabas; Leyla Kılıc; Serkan Keskın; Ibrahım Yıldız
Journal:  Int J Clin Oncol       Date:  2012-09-21       Impact factor: 3.402

5.  Role of survivor bias in pancreatic cancer case-control studies.

Authors:  Zhen-Huan Hu; John E Connett; Jian-Min Yuan; Kristin E Anderson
Journal:  Ann Epidemiol       Date:  2015-11-14       Impact factor: 3.797

6.  Locally Advanced or Metastatic Pancreatic Adenocarcinoma: Easily Available Factors of Predictive Prolonged Survival Under Gemcitabine.

Authors:  Anne Ploquin; Stephanie Truant; Guillaume Piessen; Perrine Vuagnat; Capucine Baldini; Stephane Cattan; Mohamed Hebbar
Journal:  In Vivo       Date:  2017 Jul-Aug       Impact factor: 2.155

7.  Effectiveness and safety of gemcitabine plus nab-paclitaxel in elderly patients with advanced pancreatic cancer: a single-center retrospective cohort study.

Authors:  Sae Ohwada; Akiko Todaka; Hiroshi Nakase; Hiromichi Shirasu; Takeshi Kawakami; Satoshi Hamauchi; Takahiro Tsushima; Tomoya Yokota; Yusuke Onozawa; Hirofumi Yasui; Kentaro Yamazaki
Journal:  Invest New Drugs       Date:  2022-07-28       Impact factor: 3.651

Review 8.  Exocrine pancreatic insufficiency in adults: a shared position statement of the Italian Association for the Study of the Pancreas.

Authors:  Raffaele Pezzilli; Angelo Andriulli; Claudio Bassi; Gianpaolo Balzano; Maurizio Cantore; Gianfranco Delle Fave; Massimo Falconi
Journal:  World J Gastroenterol       Date:  2013-11-28       Impact factor: 5.742

9.  Pancreatic Ductal Adenocarcinoma is Spread to the Peripancreatic Soft Tissue in the Majority of Resected Cases, Rendering the AJCC T-Stage Protocol (7th Edition) Inapplicable and Insignificant: A Size-Based Staging System (pT1: ≤2, pT2: >2-≤4, pT3: >4 cm) is More Valid and Clinically Relevant.

Authors:  Burcu Saka; Serdar Balci; Olca Basturk; Pelin Bagci; Lauren M Postlewait; Shishir Maithel; Jessica Knight; Bassel El-Rayes; David Kooby; Juan Sarmiento; Takashi Muraki; Irma Oliva; Sudeshna Bandyopadhyay; Gizem Akkas; Michael Goodman; Michelle D Reid; Alyssa Krasinskas; Rhonda Everett; Volkan Adsay
Journal:  Ann Surg Oncol       Date:  2016-01-29       Impact factor: 5.344

10.  Tumor size as measured at initial X-ray examination, not length of bile duct stricture, predicts survival in patients with unresectable pancreatic cancer.

Authors:  Henrik Forssell; Katrin Pröh; Michael Wester; Hans Krona
Journal:  BMC Cancer       Date:  2012-09-25       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.